Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples.
about
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?Characterization of DNA Methylation in Circulating Tumor CellsEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Genetic and Epigenetic Alterations in Bladder CancerThe somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cellsMethylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population.Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologiesVimentin DNA methylation predicts survival in breast cancerNegative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma.Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylationAltered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations.The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancersA screening-testing approach for detecting gene-environment interactions using sequential penalized and unpenalized multiple logistic regressionContralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylationIdentification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.Expression, function, and regulation of the testis-enriched heat shock HSPA2 gene in rodents and humans.Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinomaAnticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selectionFiltration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer.Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cellsExploring the Molecular Mechanism and Biomakers of Liver Cancer Based on Gene Expression MicroarrayEpigenetic alterations in bladder cancer and their potential clinical implications.Bladder cancer: a simple model becomes complex.Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma.DNA hypermethylation of the vimentin gene inversely correlates with vimentin expression in intestinal- and diffuse-type gastric cancerTranscriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer.Pathogenic Network Analysis Predicts Candidate Genes for Cervical Cancer.An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han ChineseMethylated DNA and microRNA in body fluids as biomarkers for cancer detection.Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.Prognostic significance of MST1R dysregulation in renal cell tumorsNoninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence.The role of vimentin as a methylation biomarker for early diagnosis of cervical cancerEpigenetic research in cancer epidemiology: trends, opportunities, and challengesUroMark-a urinary biomarker assay for the detection of bladder cancer.Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder CancerHypomethylating agents for urologic cancers.
P2860
Q26744146-5C9EFF6D-A423-4046-88E9-C6A3DEB1BB33Q26778427-05A8BD96-A266-476F-AF87-1566164ADCD2Q26827810-7EA45730-D5C2-4F0D-8FF1-AD26AA91DC2CQ28074732-DFBD9C88-ADED-4B32-AA08-C6EDF4207D07Q28484664-D76526D0-1722-4FC8-8EC1-00D717FA6DCEQ31058055-4DA15FCE-B2E5-4E0C-9053-1AAC01A8868FQ33929637-35AB73BD-FD5D-49FC-854A-BF78C2E2DEF7Q34030606-5B05B3AE-B86F-4FF1-910C-F8BCC4928A7AQ34034767-2282421E-CA7B-4B78-9817-331EEB2070A5Q34255579-1D598900-4FC1-424B-A63B-6547ACD4DBEDQ34441297-D135033E-A7DE-433D-82A4-836874572EA3Q34625644-DE9FF188-DAB1-4B81-851A-4CBC0158B563Q34776216-A518BC02-1C9D-4C59-8311-18335D2F1CE2Q34988246-D348329B-8863-456B-9A0B-0120C2301E46Q35017773-D16F74EB-2EB1-42D7-950D-340174F02DA4Q35048563-F5B3BF78-0AEE-43FA-A497-7D113BFC4792Q35078830-3DC2B5AF-0835-4D7C-8EA7-4768AE6FBCA9Q35147519-A59F3B02-2178-4281-8B47-A888B580C8ABQ35475302-5D8EC0BC-B00B-43B9-BE56-442B3C1BA244Q35677556-2A92B064-3F33-49EF-A43D-77BE87E1B802Q35685060-D72B9C65-3C70-43BC-A146-3E4E1C81A89DQ35926034-8565F383-800B-49DE-B32C-56189926C424Q35998684-E94CBEFF-DB3C-4783-80B5-A0D0C2CEE523Q36095721-E9EB3D77-38B1-4369-AD53-4C5767BBAE13Q36108115-24369CFD-576D-4113-8D39-8CA82CF77546Q36190604-ADBFC08D-8A8F-4732-84FF-62DA84B480BBQ36319775-67F8AE61-730C-450F-9CF2-4B05E3A966F6Q36503180-09CB1DB8-D069-48B6-83BB-A1FD6C8C3860Q36672637-866FFE8A-57E2-4663-8F63-4D8C7E4A5506Q36680727-A4C3DC99-EDA8-4856-BB8E-F1BCE5615460Q36771937-17A1C257-B182-42B4-B908-E22D5A7D8C54Q36913739-9422E3DD-0AFF-4E98-87E9-B710724D4AC9Q37191063-37F1BD4A-A12C-4CAE-B556-3038A536239AQ37215552-5B1AFE99-5A44-470E-B5F3-C7D783DFE45CQ37250675-4D5AB9C9-D660-480C-BFF8-82A6C51380FDQ37460979-219705B3-C049-418E-9205-FDC8AF2C6CC6Q37587537-0485897E-9555-4445-A80C-ECF2D81BAC78Q37615895-8AE6BB8E-2406-4E3A-90CD-9505AE0C942FQ37627004-155B885F-7548-42D3-A6DC-210FDEA9BF92Q37854737-54716B4B-D165-4D7C-A5BD-55587D86770D
P2860
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@en
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@nl
type
label
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@en
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@nl
prefLabel
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@en
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@nl
P2093
P50
P1476
Three epigenetic biomarkers, G ...... sed analyses of urine samples.
@en
P2093
Angelo Rodrigues
Guro E Lind
Jorge Oliveira
José S Magalhães
Mette Eknaes
Sara Duarte-Pereira
Stine A Danielsen
Vera L Costa
P304
P356
10.1158/1078-0432.CCR-10-1312
P407
P577
2010-10-25T00:00:00Z